MX384151B - Variantes de desintegrina y usos farmacéuticos de las mismas. - Google Patents

Variantes de desintegrina y usos farmacéuticos de las mismas.

Info

Publication number
MX384151B
MX384151B MX2017002323A MX2017002323A MX384151B MX 384151 B MX384151 B MX 384151B MX 2017002323 A MX2017002323 A MX 2017002323A MX 2017002323 A MX2017002323 A MX 2017002323A MX 384151 B MX384151 B MX 384151B
Authority
MX
Mexico
Prior art keywords
disintegrin variants
pharmaceutical uses
disintegrin
variants
integrin
Prior art date
Application number
MX2017002323A
Other languages
English (en)
Other versions
MX2017002323A (es
Inventor
Woei-Jer Chuang
Original Assignee
Univ Nat Cheng Kung
Dcb Usa Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nat Cheng Kung, Dcb Usa Llc filed Critical Univ Nat Cheng Kung
Publication of MX2017002323A publication Critical patent/MX2017002323A/es
Publication of MX384151B publication Critical patent/MX384151B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6418—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals from snakes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)

Abstract

La presente invención se refiere a variantes de desintegrina que se unen específicamente a uno o más de a5ß1 e integrinas av, tales como avß1, avß3, avß5, avß6 y avß8, pero con una reducción en la actividad de unión a aIIbß3; también se describen los usos de las variantes de desintegrina para el tratamiento o prevención de una enfermedad asociada con una integrina av o una integrina a5ß1.
MX2017002323A 2014-08-22 2015-08-21 Variantes de desintegrina y usos farmacéuticos de las mismas. MX384151B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462040503P 2014-08-22 2014-08-22
PCT/US2015/046322 WO2016029131A1 (en) 2014-08-22 2015-08-21 Disintegrin variants and pharmaceutical uses thereof

Publications (2)

Publication Number Publication Date
MX2017002323A MX2017002323A (es) 2017-08-02
MX384151B true MX384151B (es) 2025-03-14

Family

ID=55351297

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002323A MX384151B (es) 2014-08-22 2015-08-21 Variantes de desintegrina y usos farmacéuticos de las mismas.

Country Status (12)

Country Link
US (2) US10508137B2 (es)
EP (1) EP3182988A4 (es)
JP (1) JP6886917B2 (es)
KR (1) KR102102789B1 (es)
CN (1) CN106714818B (es)
AU (1) AU2015305299B2 (es)
CA (1) CA2958906C (es)
MX (1) MX384151B (es)
RU (1) RU2685869C1 (es)
SG (1) SG11201700114WA (es)
TW (2) TWI563001B (es)
WO (1) WO2016029131A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6886917B2 (ja) * 2014-08-22 2021-06-16 國立成功大學Ｎａｔｉｏｎａｌ Ｃｈｅｎｇ Ｋｕｎｇ Ｕｎｉｖｅｒｓｉｔｙ ロドストミンバリアント、ロドストミンバリアントをコードするポリヌクレオチド、当該ポリヌクレオチドを含む組換え宿主細胞、及びロドストミンバリアントを含む医薬組成物
WO2017001990A1 (en) 2015-06-28 2017-01-05 Allgenesis Biotherapeutics Inc. Fusion proteins for inhibiting angiogenesis
IL247369B (en) * 2016-08-18 2018-08-30 B G Negev Tech And Applications Ltd Polypeptides derived from CSF-m and their uses
US11332498B2 (en) 2017-03-17 2022-05-17 Technische Universitat Munchen Ligands for integrin αVβ8, synthesis and uses thereof
CA3072163C (en) * 2017-08-09 2022-09-20 National Cheng Kung University Disintegrin variants and uses thereof
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380646A (en) * 1992-10-19 1995-01-10 Temple University Of The Commonwealth System Of Higher Education Thrombus detection using radiolabelled disintegrins
US7220724B2 (en) * 1993-10-22 2007-05-22 University Of Southern California Contortrostatin CN and methods for its use in preventing metastasis and other conditions
US7452551B1 (en) * 2000-10-30 2008-11-18 Imarx Therapeutics, Inc. Targeted compositions for diagnostic and therapeutic use
EP2213743A1 (en) * 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
NZ567952A (en) * 2003-03-24 2009-12-24 Sequoia Pharmaceuticals Inc Long acting biologically active conjugates
US7943728B2 (en) * 2006-12-26 2011-05-17 National Cheng Kung University Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases
US8183201B2 (en) * 2006-12-26 2012-05-22 National Cheng Kung University Methods of treating αvβ3 integrin-associated diseases by administering polypeptides selective for αvβ3 integrin
KR20120097481A (ko) * 2009-07-20 2012-09-04 내셔날 쳉쿵 유니버시티 사람 혈청 알부민(ＨＳＡ)의 변이체와 컨쥬게이션된 αｖβ3 인테그린에 대해 선택적인 폴리펩타이드 및 이의 약제학적 용도
NZ600544A (en) * 2009-12-23 2014-06-27 Univ Nat Cheng Kung Compositions and methods for the treatment of angiogenesis-related eye diseases
EP2534171A4 (en) * 2010-02-11 2013-07-17 Univ Southern California MODIFIED ADAM DISINTEGRIN DOMAIN POLYPEPTIDES AND USES THEREOF
US8946159B2 (en) * 2011-12-22 2015-02-03 California Northstate College Of Pharmacy, Llc Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment
WO2015048354A1 (en) * 2013-09-25 2015-04-02 Markland Francis S Jr Compositions and methods for treating ovarian cancer including preventing the recurrence thereof
JP6886917B2 (ja) * 2014-08-22 2021-06-16 國立成功大學Ｎａｔｉｏｎａｌ Ｃｈｅｎｇ Ｋｕｎｇ Ｕｎｉｖｅｒｓｉｔｙ ロドストミンバリアント、ロドストミンバリアントをコードするポリヌクレオチド、当該ポリヌクレオチドを含む組換え宿主細胞、及びロドストミンバリアントを含む医薬組成物
WO2017001990A1 (en) * 2015-06-28 2017-01-05 Allgenesis Biotherapeutics Inc. Fusion proteins for inhibiting angiogenesis

Also Published As

Publication number Publication date
MX2017002323A (es) 2017-08-02
BR112017003334A8 (pt) 2018-02-06
WO2016029131A1 (en) 2016-02-25
CN106714818A (zh) 2017-05-24
RU2017105771A3 (es) 2018-09-24
TW201708250A (zh) 2017-03-01
TWI563001B (en) 2016-12-21
RU2017105771A (ru) 2018-09-24
JP2017525394A (ja) 2017-09-07
US10870684B2 (en) 2020-12-22
US20200010516A1 (en) 2020-01-09
AU2015305299B2 (en) 2018-11-01
TWI579299B (zh) 2017-04-21
CA2958906A1 (en) 2016-02-25
CA2958906C (en) 2021-05-04
EP3182988A1 (en) 2017-06-28
AU2015305299A1 (en) 2017-02-09
JP6886917B2 (ja) 2021-06-16
KR102102789B1 (ko) 2020-04-24
CN106714818B (zh) 2020-04-21
KR20170042366A (ko) 2017-04-18
US20170267731A1 (en) 2017-09-21
TW201609793A (zh) 2016-03-16
RU2685869C1 (ru) 2019-04-23
EP3182988A4 (en) 2018-05-23
US10508137B2 (en) 2019-12-17
SG11201700114WA (en) 2017-02-27
BR112017003334A2 (pt) 2017-11-28

Similar Documents

Publication Publication Date Title
MX384151B (es) Variantes de desintegrina y usos farmacéuticos de las mismas.
HRP20190258T8 (hr) Ambalažna konstrukcija i postupci proizvodnje navedene ambalažne konstrukcije
EP2958536C0 (en) PACKAGING KIT FOR STORING TISSUE OR CELLULAR MATERIAL
EP2897593A4 (en) BIOABCABLE MICRO CAPSULES WITH A FILLING MATERIAL
HUE037310T2 (hu) Módosított botulinum neurotoxin
PT3205720T (pt) Vetor de expressão de car e células t que expressam car
EP3009547A4 (en) FABRIC AND TEXTILE PRODUCT THEREFOR
HUE045646T2 (hu) Komplement aktivitás modulálása
EP2964022A4 (en) ANALGIC COMBINATION AND USE
EP2920744A4 (en) DYNAMIC TASK MANAGEMENT
CL2014002326A1 (es) Combinacion que comprende benzodioxanos y uno o mas agentes activos y su uso en el tratamiento de enfermedades tales como ateroesclerosis e infarto al miocardio.
IL239478B (en) Prophylactic/therapeutic agent for dry eye
EP3872134C0 (de) Polymerzusammensetzung enthaltend plla und pdla
DK3347084T3 (da) Aortakanyle til ex vivo-organplejesystem
UY34603A (es) Anticuerpos anti-asic-1 y usos de los mismos
EP3579960A4 (en) ISOTHERMAL REACTOR
EP2928463A4 (en) LYOPHILIZED PREPARATIONS OF MELPHALAN FLUFENAMIDE
PT2804475T (pt) Criopreservação de células, tecidos e órgãos
SMT201500320B (it) Liofilizzazione di agente tensioattivo polmonare liposomale sintetico
EP2983661C0 (en) OXABICYCLOHEPTANE AND OXABICYCLOHEPTENE FORMULATIONS
HUE056613T2 (hu) Komplementaktivitás modulátorai
NI201400091S (es) Envase
CL2016000462A1 (es) Ensamble estructural y método de ensamble del mismo
EP2978841A4 (en) ENTEROCOCCUS FAECALIS BACTERIOPHAGES AND USES THEREOF
IL248629B (en) Cycloalkyl-linked diheterocycle derivatives